-
In the future, the pace of overseas listing of new domestic drugs will continue to accelerate
Time of Update: 2021-12-08
On October 26, Lunan Pharmaceutical received an approval letter from the US FDA regarding the addition of the Shandong New Times Pharmaceuticals production site to the rosuvastatin calcium tablets ANDA (a brief application for new drugs), marking the ANDA rosuvastatin calcium produced by Lunan Pharmaceuticals The film can be sold in the US market .
-
Another city!
Time of Update: 2021-12-08
On November 9th, Astellas and Baiyang Pharmaceutical have joined hands, and the two parties have discussed the original research drugs of Astellas Betantil (Mirabegron sustained-release tablets), Weixikang (Sorinasine succinate tablets) and The promotion and operation of Halo (tamsulosin hydrochloride sustained-release capsules) in mainland China reached a deepening cooperation agreement, which will jointly explore the commercialization of urinary treatment drugs, improve drug availability, and better serve Chinese patients with urinary diseases .
-
Deepen cooperation!
Time of Update: 2021-12-08
They continue to increase their investment in China, try their best to meet the unmet medical needs of Chinese patients, and at the same time accelerate the pace of their innovative products entering the market, ensure the demand for clinical treatment, and expand the availability of drugs .
-
In order to strengthen digital capabilities, pharmaceutical companies have begun to "hand in hand" with Internet medical companies
Time of Update: 2021-12-08
Recently, at the 4th China International Import Expo in 2021, Hanhui Pharmaceutical and Huiyi World Internet Medical Platform signed a strategic cooperation agreement .
Professionalism, depth, openness, and cooperation models will be the new development trend of the pharmaceutical industry, and the Internet platform and digital technology will become its strong driving force .
-
Gale announced that the Phase II clinical trial application of ASC22 (envolimab) for immune reconstitution/functional cure of human immunodeficiency virus type 1 (HIV-1) infected persons has been approved by the State Food and Drug Administration of China
Time of Update: 2021-12-08
(Hong Kong Stock Exchange code: 1672) today announced that its ASC22 (Envolimab) Phase II clinical trial application has been approved by China Approved by the National Medical Products Administration (NMPA) as a new indication for immune reconstitution/functional cure for people infected with human immunodeficiency virus type 1 (HIV-1) .
-
Three quarterly reports exceed expectations, many pharmaceutical machinery companies are optimistic about institutions
Time of Update: 2021-12-08
In response to the three quarterly reports of Chutian, Tofflon and other listed pharmaceutical machinery companies exceeding expectations, a number of institutions issued "optimistic" research reports and maintained a "buy" rating .
-
With the huge potential of China's ophthalmology market, it faces three major challenges
Time of Update: 2021-12-08
This time, Shengdi Medicine's tafluprost eye drops are planned to be included in the priority review, which means that the drug is expected to be approved for marketing at an accelerated rate, thereby bringing new choices to more glaucoma patients .
-
Kanghong Pharmaceutical Industry Vothiaxetine Hydrobromide Tablets Obtained Drug Registration Certificate
Time of Update: 2021-12-08
On November 10, Kanghong Pharmaceutical issued an announcement stating that the generic drug of Futhiaxetine hydrobromide tablets had recently been approved for marketing by the National Medical Products Administration .
-
With favorable policies, Chinese medicine will play an important role in children's health care services
Time of Update: 2021-12-08
In addition, in May this year, the National Health Commission and the State Administration of Traditional Chinese Medicine also jointly issued the "Implementation Plan for Promoting Chinese Medicine in the Field of Maternal and Child Health (2021-2025)", which clearly stated that they would promote the development of Chinese medicine services in maternal and child health institutions.
-
Green development has become the general trend of the industry, and pharmaceutical companies are taking multiple measures to respond
Time of Update: 2021-12-08
Under the background that the country vigorously promotes green environmental protection and sustainable development, the construction of China's ecological civilization has entered a period of accele
-
The tens of billions of migraine drugs market will usher in new changes!
Time of Update: 2021-12-08
It is understood that in addition to Pfizer's continuous work on CGRP receptor inhibitors, companies such as Amgen and Teva have also begun to develop new CGRP targeted drugs .
As a new type of drug, migraine drugs based on CGRP antibodies will have a huge space for future development .
-
The peptide drug industry is developing rapidly, and this "troika" will continue to drive market growth
Time of Update: 2021-12-08
At present, there are more than 40 peptide drugs on the market in China, which mainly involve seven major fields, including immunity, digestive tract, anti-tumor, orthopedics, obstetrics, diabetes and cardiovascular .
-
Two styles a day! Hengrui Medicine's anesthetics and eye drops were approved for listing in China today
Time of Update: 2021-12-08
According to the public information disclosed by Hengrui Medicine, it is speculated that the new indication for the drug approved this time may be general anesthesia or bronchoscopy sedation .
-
Domestic pharmaceutical companies are accumulating in the field of anti-tumor drugs, and good news comes out frequently
Time of Update: 2021-12-08
For example, on November 8, Hengrui Medicine issued an announcement stating that two anti-tumor drugs with a research and development investment of over 640 million yuan were approved for clinical trials .
-
Shenzhen's strategy for monitoring and management of drug prices: 4491 pharmacies’ medical insurance drug prices are “in your hands” at any time
Time of Update: 2021-12-08
On November 10, the Shenzhen Municipal Medical Insurance Bureau launched the "Medicare Drug Price Link" medical insurance drug price inquiry service, covering 4,491 designated retail pharmacies in the city .
-
In order to accelerate innovation, pharmaceutical companies set off a "wave of cooperation"
Time of Update: 2021-12-08
For example, on November 10, Tianjing Bio announced that it had reached a product development, production and commercialization cooperation with Jichuan Pharmaceutical on the highly differentiated long-acting recombinant human growth hormone eftansomatropin alfa (eftansomatropin alfa, TJ101) .
-
Phase IIb China study of ADC drug targeting TROP2 triple-negative breast cancer reaches its primary endpoint
Time of Update: 2021-12-08
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn November 11, Genting Shinyao and Gilead Sciences jointly announced a phase IIb clinical trial of gosartuzumab (US trade name: Trodelvy) for the treatment of metastatic triple-negative breast cancer (TNBC) (EVER-132-001) Reached its primary endpoint of overall response rate (ORR) .
-
Drug Administration issued a document to regulate online prescription drugs
Time of Update: 2021-12-08
The "Regulations" stated that when pharmaceutical retail companies sell prescription drugs online, they should ensure that the source of electronic prescriptions is authentic and reliable, conduct prescription deployment reviews in strict accordance with relevant requirements, and mark the use of electronic prescriptions that have been used .
-
A large number of multinational pharmaceutical companies are accelerating cooperation with Internet platforms to enhance their digital capabilities
Time of Update: 2021-12-08
The two parties announced that they will carry out in-depth cooperation based on the advantages of Dingdang Kuaiyao's integrated online and offline "digital pharmacy" model, the digitalization of pharmaceutical services, and AstraZeneca's outstanding drug research and development capabilities and years of experience in the health business field .
-
What direction does the 2021 policy of the pharmaceutical equipment industry indicate for the development of the industry?
Time of Update: 2021-12-08
Judging from these two documents, green, low-carbon, high-end equipment with a high level of automation will be the next direction for the API equipment industry to continue its efforts and research .
